- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Multibillion Spent on Drug Development, But Is It Helping?
While the pharmaceutical industry has always justified the billions spent on developing a candidate drug molecule, the process has definitely seen some important changes. This article evaluates whether these revolutionary changes have influenced drug development for the better.
In November 2014, Tufts Center for Drug Discovery announced it takes $2.6 billion to push a drug through development and marketing approval—a process that often spans longer than 10 years.
This eye-opening amount of time and money was, of course, met with some skepticism from consumer groups and the media, which argued that the Tufts research—partially funded by drug makers—could simply be trying to justify rising drug prices. (Both The Wall Street Journal blog and The New York Times published pieces highlighting the ways critics approached the news release.)
But critics aside, it’s figures such as these that are inspiring the industry to find new ways to speed drug development. The solutions will vary depending on the type of treatment and the resources available to the companies developing these drugs.
Read the complete article at Bioprocess Online: http://bit.ly/1BSzJJB
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
